Literature DB >> 19887491

Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors.

Hsuan-Ying Huang1, Shau-Hsuan Li, Shih-Chen Yu, Fong-Fu Chou, Ching-Cherng Tzeng, Tsung-Hui Hu, Yih-Huei Uen, Yu-Fang Tian, Yu-Hui Wang, Fu-Min Fang, Wen-Wei Huang, Yu-Ching Wei, Jing-Mei Wu, Chien-Feng Li.   

Abstract

PURPOSE: Chromosome 9 is frequently deleted in high-risk gastrointestinal stromal tumors (GISTs), whereas its specific tumor suppressor genes (TSGs) are less understood. We did an integrative study of MTAP gene at 9p21 to analyze its implication in GISTs. EXPERIMENTAL
DESIGN: To search TSGs on chromosome 9, we used ultrahigh-resolution array comparative genomic hybridization to profile DNA copy number alterations of 22 GISTs, with special attention to MTAP gene. MTAP immunoexpression was assessable for 306 independent GISTs on tissue microarrays, with 146 cases analyzed for MTAP homozygous deletion, 181 for mutations of KIT and PDGFRA receptor tyrosine kinase genes, and 7 for MTAP hypermethylation.
RESULTS: Array comparative genomic hybridization identified 11 candidate TSGs on 9p and six on 9q. MTAP and/or CDKN2A/CDKN2B at 9p21.3 were deleted in one intermediate-risk (11%) and seven high-risk (70%) GISTs with two cases homozygously codeleted at both loci. MTAP homozygous deletion, present in 25 of 146 cases, was highly associated with larger size and higher mitotic rate, Ki-67 index, and risk level (all P < 0.01) but not with receptor tyrosine kinase genotypes. Whereas MTAP homozygous deletion correlated with MTAP protein loss (P < 0.001), 7 of 30 GISTs without MTAP expression did not show homozygous deletion, including three MTAP-hypermethylated cases. MTAP homozygous deletion was univariately predictive of decreased disease-free survival (P < 0.0001) and remained multivariately independent (P = 0.0369, hazard ratio = 2.166), together with high-risk category (P < 0.0001), Ki-67 index >5% (P = 0.0106), and nongastric location (P = 0.0416).
CONCLUSIONS: MTAP homozygous deletion, the predominant mechanism to deplete protein expression, is present in 17% of GISTs. It correlates with important prognosticators and independently predicts worse outcomes, highlighting the role in disease progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19887491     DOI: 10.1158/1078-0432.CCR-09-1511

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  19 in total

1.  Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine.

Authors:  Baiqing Tang; Hyung-Ok Lee; Serim S An; Kathy Q Cai; Warren D Kruger
Journal:  Cancer Res       Date:  2018-05-29       Impact factor: 12.701

Review 2.  6-thioguanine: a drug with unrealized potential for cancer therapy.

Authors:  Pashna N Munshi; Martin Lubin; Joseph R Bertino
Journal:  Oncologist       Date:  2014-06-13

Review 3.  Gastrointestinal stromal tumours: origin and molecular oncology.

Authors:  Christopher L Corless; Christine M Barnett; Michael C Heinrich
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

4.  Primate genome gain and loss: a bone dysplasia, muscular dystrophy, and bone cancer syndrome resulting from mutated retroviral-derived MTAP transcripts.

Authors:  Olga Camacho-Vanegas; Sandra Catalina Camacho; Jacob Till; Irene Miranda-Lorenzo; Esteban Terzo; Maria Celeste Ramirez; Vern Schramm; Grace Cordovano; Giles Watts; Sarju Mehta; Virginia Kimonis; Benjamin Hoch; Keith D Philibert; Carsten A Raabe; David F Bishop; Marc J Glucksman; John A Martignetti
Journal:  Am J Hum Genet       Date:  2012-03-29       Impact factor: 11.025

Review 5.  Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.

Authors:  Joseph R Bertino; William R Waud; William B Parker; Martin Lubin
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

6.  Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.

Authors:  Colin C Collins; Stanislav V Volik; Anna V Lapuk; Yuwei Wang; Peter W Gout; Chunxiao Wu; Hui Xue; Hongwei Cheng; Anne Haegert; Robert H Bell; Sonal Brahmbhatt; Shawn Anderson; Ladan Fazli; Antonio Hurtado-Coll; Mark A Rubin; Francesca Demichelis; Himisha Beltran; Martin Hirst; Marco Marra; Christopher A Maher; Arul M Chinnaiyan; Martin Gleave; Joseph R Bertino; Martin Lubin; Yuzhuo Wang
Journal:  Mol Cancer Ther       Date:  2012-01-17       Impact factor: 6.261

7.  FGFR2::TACC2 fusion as a novel KIT-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor.

Authors:  Josephine K Dermawan; Chad M Vanderbilt; Jason C Chang; Brian R Untch; Samuel Singer; Ping Chi; William D Tap; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2022-02-22       Impact factor: 4.263

8.  Identification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data.

Authors:  Junhua Zhang; Shihua Zhang; Yong Wang; Xiang-Sun Zhang
Journal:  BMC Syst Biol       Date:  2013-10-14

9.  Downregulated MTAP expression in myxofibrosarcoma: A characterization of inactivating mechanisms, tumor suppressive function, and therapeutic relevance.

Authors:  Chien-Feng Li; Fu-Min Fang; Hsing-Jien Kung; Li-Tzong Chen; Jun-Wen Wang; Jen-Wei Tsai; Shih Chen Yu; Yu-Hui Wang; Shau-Hsuan Li; Hsuan-Ying Huang
Journal:  Oncotarget       Date:  2014-11-30

10.  Ocular expression and distribution of products of the POAG-associated chromosome 9p21 gene region.

Authors:  Glyn Chidlow; John P M Wood; Shiwani Sharma; David P Dimasi; Kathryn P Burdon; Robert J Casson; Jamie E Craig
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.